José Manuel
Aramendía Beitia
Consultor Médico
Publications (46) José Manuel Aramendía Beitia publications
2024
-
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)
International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945
-
Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line
Clinical and Translational Oncology
2023
-
A pharmacometrics model to define docetaxel target in early breast cancer
British Journal of Clinical Pharmacology, Vol. 89, Núm. 2, pp. 727-736
2022
-
A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
Cancers, Vol. 14, Núm. 12
2021
-
Intraoperative electron beam radiotherapy and perioperative high-dose-rate brachytherapy in previously irradiated oligorecurrent gynecological cancer: clinical outcome analysis
Clinical and Translational Oncology, Vol. 23, Núm. 9, pp. 1934-1941
-
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes
British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149
2020
-
Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital
European Journal of Gynaecological Oncology, Vol. 41, Núm. 6, pp. 906-912
-
The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer
European Journal of Gynaecological Oncology, Vol. 41, Núm. 4, pp. 523-530
2019
-
Dietary inflammatory index and incidence of breast cancer in the SUN project
Clinical Nutrition, Vol. 38, Núm. 5, pp. 2259-2268
2018
-
Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience
Breast Journal, Vol. 24, Núm. 4, pp. 473-479
-
Erratum: Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial (Brachytherapy (2018) 17(5) (734–741), (S1538472118300898) (10.1016/j.brachy.2018.04.007))
Brachytherapy
-
Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial
Brachytherapy, Vol. 17, Núm. 5, pp. 734-741
2016
-
Long-Term Results of a Phase II Trial of Concomitant Cisplatin-Paclitaxel Chemoradiation in Locally Advanced Cervical Cancer
International Journal of Gynecological Cancer, Vol. 26, Núm. 6, pp. 1162-1168
-
Multicatheter breast implant during breast conservative surgery: Novel approach to deliver accelerated partial breast irradiation
Brachytherapy, Vol. 15, Núm. 4, pp. 485-494
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2015
-
37th Annual San Antonio Breast Cancer Symposium. Summary of the most important translational and clinical contributions
Revista de Senologia y Patologia Mamaria
-
Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors
Minerva Chirurgica
-
Utility of delayed reading of intradermal test in carboplatin-induced drug hypersensitivity
Annals of Allergy, Asthma and Immunology, Vol. 114, Núm. 6, pp. 534-535
2013
2011
-
A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation
Oncology Letters, Vol. 2, Núm. 5, pp. 807-809